Posterior talar process as a suitable cell source for treatment of cartilage and osteochondral defects of the talus.
Osteochondral defects of the ankle are common lesions affecting the talar cartilage and subchondral bone. Current treatments include cell-based therapies but are frequently associated with donor-site morbidity. Our objective is to characterize the posterior process of the talus (SP) and the os trigonum (OT) tissues and investigate their potential as a new source of viable cells for application in tissue engineering and regenerative medicine. SP and OT tissues obtained from six patients were characterized by micro-computed tomography and histological, histomorphometric and immunohistochemical analyses. Proliferation and viability of isolated cells were evaluated by MTS assay, DNA quantification and live/dead staining. The TUNEL assay was performed to evaluate cell death by apoptosis. Moreover, the production of extracellular matrix was evaluated by toluidine blue staining, whereas cells phenotype was investigated by flow cytometry. Characterization of ankle explants showed the presence of a cartilage tissue layer in both SP and OT tissues, which represented at least 20%, on average, of the explant. The presence of type II collagen was detected in the extracellular matrix. Isolated cells presented a round morphology typical of chondrocytes. In in vitro studies, cells were viable and proliferating for up to 21 days of culture. No signs of apoptosis were detected. Flow-cytometry analysis revealed that isolated cells maintained the expression of several chondrocytic markers during culture. The results indicated that the SP and OT tissues were a reliable source of viable chondrocytes, which could find promising applications in ACI/MACI strategies with minimal concerns regarding donor zone complications. Copyright © 2015 John Wiley & Sons, Ltd.
3Bs Research Group, Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, 4805-017, Barco, Guimarães, Portugal.|ICVS/3Bs, PT Government Associate Laboratory, Braga/Guimarães, Portugal.
S I
SI
Correia
3Bs Research Group, Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, 4805-017, Barco, Guimarães, Portugal.|ICVS/3Bs, PT Government Associate Laboratory, Braga/Guimarães, Portugal.
J
J
Silva-Correia
3Bs Research Group, Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, 4805-017, Barco, Guimarães, Portugal.|ICVS/3Bs, PT Government Associate Laboratory, Braga/Guimarães, Portugal.|Clínica do Dragão - Espregueira-Mendes Sports Centre - FIFA Medical Centre of Excellence, F.C. Porto Stadium, Minho University and Porto University Research Centre, Portugal.|Orthopaedic Department Centro Hospitalar Póvoa de Varzim, Vila do Conde, Portugal.
H
H
Pereira
3Bs Research Group, Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, 4805-017, Barco, Guimarães, Portugal.|ICVS/3Bs, PT Government Associate Laboratory, Braga/Guimarães, Portugal.
R F
RF
Canadas
3Bs Research Group, Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, 4805-017, Barco, Guimarães, Portugal.|ICVS/3Bs, PT Government Associate Laboratory, Braga/Guimarães, Portugal.
A
A
da Silva Morais
3Bs Research Group, Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, 4805-017, Barco, Guimarães, Portugal.|Stemmatters, Biotecnologia e Medicina Regenerativa SA, 4805-017, Guimarães, Portugal.
A M
AM
Frias
3Bs Research Group, Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, 4805-017, Barco, Guimarães, Portugal.|Stemmatters, Biotecnologia e Medicina Regenerativa SA, 4805-017, Guimarães, Portugal.
R A
RA
Sousa
Clínica do Dragão - Espregueira-Mendes Sports Centre - FIFA Medical Centre of Excellence, F.C. Porto Stadium, Minho University and Porto University Research Centre, Portugal.|Orthopaedic Department, Amsterdam Medical Centre, The Netherlands.
C N
CN
van Dijk
3Bs Research Group, Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, 4805-017, Barco, Guimarães, Portugal.|ICVS/3Bs, PT Government Associate Laboratory, Braga/Guimarães, Portugal.|Clínica do Dragão - Espregueira-Mendes Sports Centre - FIFA Medical Centre of Excellence, F.C. Porto Stadium, Minho University and Porto University Research Centre, Portugal.
J
J
Espregueira-Mendes
3Bs Research Group, Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, 4805-017, Barco, Guimarães, Portugal.|ICVS/3Bs, PT Government Associate Laboratory, Braga/Guimarães, Portugal.
R L
RL
Reis
3Bs Research Group, Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, 4805-017, Barco, Guimarães, Portugal.|ICVS/3Bs, PT Government Associate Laboratory, Braga/Guimarães, Portugal.
J M
JM
Oliveira
D002356:Cartilage; D049109:Cell Proliferation; D006801:Humans; D013628:Talus / Q000166:cytology* / Q000378:metabolism*; D023822:Tissue Engineering / Q000379:methods*
Stieda process; ankle; os trigonum; osteochondral lesions; regenerative medicine; talus lesions